SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Scienc - Quaterly Results

27 Jan 2023 Evaluate
With no major difference for the quarter endedDecember 2022 , the total revenue stood at Rs. 5407.31  millions.Profit after tax improved marginally to Rs. 1049.93  millions for the quarter ended December 2022 from Rs. 1037.13 millions of corresponding previous quarter.Operating Profit saw a handsome growth to 1520.64 millions from 1495.98 millions in the quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 5407.31 5224.99 3.49 15399.00 16091.57 -4.30 21232.14 18851.65 12.63
Other Income 66.08 35.34 86.98 261.21 96.09 171.84 147.04 8.11 1713.07
PBIDT 1520.64 1495.98 1.65 4619.84 4834.58 -4.44 6307.64 5918.85 6.57
Interest 1.60 0.61 162.30 4.28 278.37 -98.46 279.62 875.47 -68.06
PBDT 1519.04 1495.37 1.58 4615.56 4556.21 1.30 6028.02 5043.38 19.52
Depreciation 107.63 97.39 10.51 305.77 283.23 7.96 378.77 333.94 13.42
PBT 1411.41 1397.98 0.96 4309.79 4272.98 0.86 5649.25 4709.44 19.96
TAX 361.48 360.85 0.17 1103.75 1074.71 2.70 1462.01 1193.63 22.48
Deferred Tax 29.70 41.49 -28.42 70.75 67.49 4.83 85.74 66.17 29.58
PAT 1049.93 1037.13 1.23 3206.04 3198.27 0.24 4187.24 3515.81 19.10
Equity 245.05 245.05 0.00 245.05 245.05 0.00 245.05 19.60 1150.26
PBIDTM(%) 28.12 28.63 -1.78 30.00 30.04 -0.14 29.71 31.40 -5.38

Alivus Life Sciences Share Price

1156.95 -2.55 (-0.22%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: